Ciphergen Presents Promising Validation Results for Ovarian Cancer Biomarkers at International Gynecologic Cancer Society Meetin
October 06 2004 - 9:00AM
PR Newswire (US)
Ciphergen Presents Promising Validation Results for Ovarian Cancer
Biomarkers at International Gynecologic Cancer Society Meeting
Protein Biomarkers Shown Potentially Useful for Multiple Clinical
Applications FREMONT, Calif., Oct. 6 /PRNewswire-FirstCall/ --
Ciphergen Diagnostics, a division of Ciphergen Biosystems, Inc.
(NASDAQ:CIPH), presented yesterday initial results of its ongoing
study to validate biomarkers for ovarian cancer and reported
progress in assay development at the meeting of the International
Gynecologic Cancer Society in Edinburgh. In a study utilizing 436
samples derived from 53 women with early-stage ovarian cancer
(stage I-II), 116 women with late-stage ovarian cancer, and 98
control women, Ciphergen and its collaborators confirmed the
down-regulation of specific variants of transthyretin and
apolipoprotein A1, two markers Ciphergen has previously reported to
be down-regulated in early stage ovarian cancer. This study was
done in collaboration with Professor Ate van der Zee, of University
Hospital Groningen, and Professor Ignace Vergote, of Universitaire
Ziekenhuizen K.U.Leuven. "These results confirm our recently
published findings, revealing the reproducibility of the markers,
when discovered using a rigorous study design," said Gail S. Page,
President of Ciphergen's Diagnostics Division. "In addition, these
results were achieved using a newly developed assay specifically
designed for these markers and read on our new instrument, the
ProteinChip(R) System 4000. This is one of the milestones we have
set for ourselves in the clinical development process." Ciphergen
Diagnostics developed a chromatographic SELDI-based assay in which
five transthyretin variants could be assayed on a Q10 ProteinChip
array and two apolipoprotein A1 variants could be assayed on an
IMAC ProteinChip array. The arrays were read on the new PCS4000.
These assays achieve CV's of
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024